Internal Medicine, Hematology & Oncology · Honolulu, HI
NPI
1437562899
Since 2014
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
3288 Moanalua Rd
Honolulu, HI, 96819
Phone (808) 432-0000
Groups this clinician bills Medicare through
Medicare paid, 2024
$202K
14,886 services
Medicare patients, 2024
41
Average age 69
Drug cost, 2024
$2.3M
652 prescriptions
Company payments, 2025
$124
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Matthew L Chase was code 96413 (chemotherapy administration), 51 times for 14 patients. In total Matthew L Chase billed 14,886 services in 54 codes, and Medicare paid $202K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-03-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 96413 Chemotherapy Administration | Office | 51 | 14 | $98.26 | $5,011 |
By year: 2022 $5,522 for 40 services; 2023 $37K for 2,444 services; 2024 $202K for 14,886 services.
Medicare prescription drug claims, 2024
In 2024, the drug Matthew L Chase prescribed most often to Medicare patients was Prednisone, with 55 prescriptions and refills. In total Matthew L Chase wrote 652 Medicare prescriptions that cost $2.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 55 | 64 | 18 | $442 |
| Anastrozole Generic | 52 | 156 | 23 | $1,504 |
| Tagrisso Osimertinib Mesylate | 49 | 49 | Under 11 | $843K |
| Xtandi Enzalutamide | 48 | 48 | Under 11 | $588K |
| Dexamethasone Generic | 47 | 50 | 18 | $658 |
| Acyclovir Generic | 31 | 79 | 11 | $828 |
| Abiraterone Acetate Generic | 29 | 29 | Under 11 | $4,314 |
| Oxycodone Hcl Generic | 28 | 28 | Under 11 | $513 |
| Hydroxyurea Generic | 26 | 60 | Under 11 | $734 |
| Lenalidomide Generic | 23 | 23 | Under 11 | $254K |
| Ondansetron Hcl Generic | 18 | 18 | 15 | $137 |
| Nivestym Filgrastim-Aafi | 15 | 15 | Under 11 | $13K |
| Alvaiz Eltrombopag Choline | 13 | 13 | Under 11 | $140K |
| Ondansetron Odt Ondansetron | 12 | 12 | 11 | $159 |
| Xarelto Rivaroxaban | 11 | 31 | Under 11 | $14K |
Brand drugs: 188 claims; generic drugs: 464 claims; opioid claims: 38.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Matthew L Chase $124 ($124 in general payments such as food, travel and fees) from 1 company. The largest payer was Syndax Pharmaceuticals, Inc. with $124.
| Company | Payments | Amount |
|---|---|---|
| Syndax Pharmaceuticals, Inc. SNDX | 1 | $124 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.